Sanofi’s BTK in­hibitor from Prin­cip­ia deal suc­ceeds in Phase 3 im­mune throm­bo­cy­tope­nia tri­al

Sanofi’s $3.7 bil­lion buy­out of Prin­cip­ia Bio­phar­ma may be start­ing to pay off af­ter a co­va­lent BTK in­hibitor it ob­tained in the deal hit the pri­ma­ry end­point in a Phase 3 test in pa­tients with an au­toim­mune blood dis­or­der.

The Phase 3 LU­NA 3 tri­al set twice-dai­ly oral rilz­abru­ti­nib — which Sanofi ac­quired dur­ing its 2020 pur­chase of Prin­cip­ia — ver­sus place­bo in adults and ado­les­cents with per­sis­tent or chron­ic im­mune throm­bo­cy­tope­nia (ITP).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER